mTOR Inhibitors Market to Grow with a CAGR of 5.54% through 2028
Growing emphasis on precision medicine and
personalized treatment is expected to drive the Global mTOR Inhibitors Market
growth in the forecast period, 2024-2028.
According to TechSci Research report, “mTOR
Inhibitors Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global mTOR Inhibitors Market
stood at USD 4.10 billion in 2022 and is anticipated to grow with a CAGR of 5.54%
in the forecast period, 2024-2028. mTOR, or mammalian target of rapamycin,
inhibitors represent an important class of drugs primarily utilized in cancer
therapy, transplantation, and certain rare diseases. According to the
World Health Organization, cancer is the second leading cause of death
worldwide. As populations grow and age, the absolute number of cancer cases
continues to rise, making the need for effective therapies more urgent. mTOR
inhibitors like everolimus and temsirolimus have demonstrated efficacy against
various cancer types, such as renal cell carcinoma and certain breast cancers.
Their success in cancer therapy has solidified their standing in the
pharmaceutical market. An often-underestimated factor driving the
pharmaceutical market,
in general, is the demographic shift towards an older
global population. Older individuals tend to have a higher susceptibility to
diseases, including cancer and autoimmune conditions. This rise in potential
patients needing therapeutic intervention naturally boosts the demand for
effective medications, including mTOR inhibitors. mTOR inhibitors are not only
vital in the fight against cancer but also play an essential role in organ
transplantation. They act as immunosuppressants, preventing the body's immune
system from rejecting transplanted organs. With the rise in successful
transplantation surgeries and a growing awareness of organ donations, the
demand for these immunosuppressant drugs has grown in tandem. While initially known for their role in cancer therapy
and transplantation, the potential therapeutic applications for mTOR inhibitors
are expanding. Recent research indicates their utility in treating autoimmune
diseases such as lupus and rheumatoid arthritis. As these potential
applications come to fruition, the market for mTOR inhibitors is set to expand
correspondingly.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global mTOR Inhibitors Market.”
The pharmaceutical industry is one that thrives on
innovation. Ongoing research and development into mTOR inhibitors have brought
forth newer generations of these drugs. For instance, dual mTORC1/mTORC2
inhibitors promise improved therapeutic outcomes and fewer side effects, paving
the way for even more extensive market acceptance. The allure of this market
segment has also drawn significant investments, bolstering research endeavors. The Global mTOR Inhibitors Market is segmented into Product
Type, Indication, End -User, Regional Distribution, And Company. Based on the Product Type, Afinitor
emerged as the dominant segment in the global market for Global mTOR Inhibitors
Market in 2022. Afinitor has received approvals for a wide range of
indications, making it versatile in treating various diseases. It is used in
oncology for the treatment of multiple cancer types, including breast cancer,
pancreatic neuroendocrine tumors, and renal cell carcinoma. It also finds
application in non-oncological conditions such as tuberous sclerosis complex
(TSC), a rare genetic disorder, and as an immunosuppressant in organ
transplantation. This broad therapeutic spectrum increases its demand across
different medical specialties and patient populations.
Based on the Distribution Channel,
Hospital Pharmacies emerged as the dominant segment in the global market for
Global mTOR Inhibitors Market in 2022. mTOR inhibitors are often administered
in a clinical setting, especially for cancer treatment or post-organ
transplantation care. Hospital pharmacies are equipped to handle the
specialized storage and administration requirements of these drugs, ensuring
proper handling and safety during the treatment process. mTOR
inhibitors require careful dosing and monitoring due to their potential for
side effects and interactions with other medications. Hospital pharmacies have
the expertise and infrastructure to provide the necessary oversight, ensuring
that patients receive the right dose and experience appropriate management of
any adverse events. Patients undergoing cancer treatment or organ
transplantation often spend time in the hospital as inpatients. Hospital
pharmacies play a central role in supplying and administering mTOR inhibitors
to these patients during their hospital stays. This is especially relevant for
critical post-transplant immunosuppression or intensive chemotherapy regimens.
Based
on the Indication, the oncology segment emerged as the dominant player in the
global market for Global mTOR Inhibitors Market in 2022. Cancer is a leading
cause of morbidity and mortality worldwide, with a continuously rising
incidence. The global cancer burden has been steadily increasing, necessitating
effective treatments. mTOR inhibitors, such as Afinitor (everolimus) and
Torisel (temsirolimus), have shown significant efficacy in several cancer
types, including breast cancer, renal cell carcinoma, pancreatic neuroendocrine
tumors, and more. As the incidence of cancer grows, so does the demand for
effective cancer therapies, driving the utilization of mTOR inhibitors in
oncology. In recent years, mTOR inhibitors have been increasingly integrated
into combination therapy regimens in oncology. Combining these drugs with other
targeted therapies or immunotherapies has shown promise in overcoming
resistance mechanisms and improving treatment outcomes. These advancements
further enhance their utilization in cancer treatment.
North America emerged as the dominant player in the
global mTOR Inhibitors Market in 2022, holding the largest market share. North
America boasts a well-established and advanced healthcare infrastructure,
characterized by state-of-the-art medical facilities, research institutions,
and a highly skilled healthcare workforce. This infrastructure supports the
development, clinical testing, and widespread adoption of innovative therapies
like mTOR inhibitors.The region is home to numerous pharmaceutical and biotechnology
companies at the forefront of mTOR inhibitor research and development. These
firms continually invest in cutting-edge research, clinical trials, and drug
discovery, contributing to the introduction of new and improved mTOR inhibitors.
Major companies operating in Global mTOR
Inhibitors Market are:
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC.
- AstraZeneca Plc
- Exelixis Inc.
- Dr. Reddy's Laboratories Ltd.
- Zydus Pharmaceuticals Inc.
- Accord Healthcare Inc.
- Par Pharmaceutical
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global mTOR
(mammalian target of rapamycin) inhibitors market is poised for significant
growth in the coming years. The ever-evolving landscape of precision medicine
is driving the demand for targeted therapies like mTOR inhibitors, which can be
tailored to individual patient profiles. Additionally, ongoing research and
development efforts are expanding the therapeutic applications of mTOR
inhibitors, further fueling market growth. The rising incidence of cancer,
autoimmune diseases, and organ transplantation procedures, coupled with the
aging global population, is amplifying the need for these innovative drugs.
Furthermore, the increasing awareness among patients and healthcare providers
about the benefits of mTOR inhibitors and their improving safety profiles are
boosting their adoption.” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“mTOR Inhibitors Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product
Type (Rapamune, Afinitor, Torisel, Zortress, Other), By Indication (Oncology,
Immunosuppressant, Organ Transplantation, Other), By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and
Competition”, has evaluated the future growth potential of Global mTOR Inhibitors
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global mTOR Inhibitors
Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com